PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Carsten Behrens	08/02/2012
Nils Langeland Johansen	08/02/2012
Henrik Sune Andersen	08/02/2012
Leif Noerskov-Lauritsen	08/02/2012
Jens Buchardt	08/02/2012

RECEIVING PARTY DATA

Name:	Novo Nordisk HealthCare AG	
Street Address:	Andreasstrasse 15	
City:	Zurich	
State/Country:	SWITZERLAND	
Postal Code:	CH-8050	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13522390

CORRESPONDENCE DATA

 Fax Number:
 6099875440

 Phone:
 609-987-5800

Email: nnipatent@novonordisk.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US

Mail.

Correspondent Name: Novo Nordisk Inc.
Address Line 1: 100 College Road West

Address Line 4: Princeton, NEW JERSEY 08540

ATTORNEY DOCKET NUMBER:	8069.204-US
NAME OF SUBMITTER:	Lori M. Klewin

Total Attachments: 2

source=8069204US_Assignment#page1.tif source=8069204US_Assignment#page2.tif

PATENT REEL: 028835 FRAME: 0827 125223

CH \$40.00

Attorney Docket No.: 8069.204-US

ASSIGNMENT OF RIGHTS IN AND RELATED TO US PATENT APPLICATION(S)

Carsten Behrens, a citizen of Denmark, residing in Koebenhavn N, Denmark;

Nils Langeland Johansen, a citizen of Denmark, residing in Koebenhavn Oe, Denmark;

Henrik Sune Andersen, a citizen of Denmark, residing in Holte, Denmark;

Leif Noerskov-Lauritsen, a citizen of Denmark, residing in Tappernoeje, Denmark;

Jens Buchardt, a citizen of Denmark, residing in Gentofte, Denmark;

(hereinafter individually ASSIGNOR), for good and valuable consideration, the receipt of which is hereby acknowledged, each independently hereby assign to NOVO NORDISK HEALTH CARE AG, a corporation organized under the laws of Switzerland, located at Andreasstrasse 15, Zurich, Switzerland CH-8050 (hereinafter ASSIGNEE), its successors, or assigns, all rights, titles, and interests in discoveries and/or inventions entitled:

Growth Hormones with Prolonged In-Vivo Efficacy,

U.S. Patent Application Number(s) 13/522,390, filed July 16, 2012, and any continuations, continuations-in-part, and/or divisions thereof, any patents arising therefrom, and any extensions, reissues, and/or reexamined patents thereof or related thereto, and all rights in any patent applications, patents, and/or similar legal instruments that may claim a priority right that is predicated upon or arises from any such applications or patents in any country.

Each ASSIGNOR independently covenants that he or she has full right to convey the entire right, title, and interest hereby assigned. Each ASSIGNOR further independently covenants that he or she will whenever called upon by ASSIGNEE, its successors, legal representatives, or assigns, communicate any known facts relating to the subject matter of the application(s) and/or related technologies; execute and deliver any and all lawful papers (including, without limitation, granting powers of attorney); make all rightful oaths, affidavits, or declarations; testify in any legal proceedings, mediations, arbitrations, or other proceedings; and perform all other lawful acts deemed by ASSIGNEE necessary or desirable to obtain, enjoy the benefit of, and perfect title in the rights hereby assigned including allowing ASSIGNEE to enforce, protect, license, or assign, any rights in the patent application(s), patents, and other rights hereby assigned.

PATENT REEL: 028835 FRAME: 0828

This ASSIGNMENT shall be binding upon each ASSIGNOR's heirs, executors, administrators, successors, and/or assigns.

Date: 48 - 2012 My Long Dol Nils Langeland Johansen

Date: 2/8-2aQ

Date: 2/8-2012

Leif Noerskov-Lauritsen

Date: 02. August 2012

Lauritsen